New York, NYNCT05332613Now EnrollingIRB Ready

Non-Alcoholic Fatty Liver Disease Clinical Trial in New York, NY

Access cutting-edge non-alcoholic fatty liver disease treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Weill Medical College of Cornell University

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access non-alcoholic fatty liver disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-alcoholic fatty liver disease treatment provided free

Apply for This New York Location

Check if you qualify for this non-alcoholic fatty liver disease clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Non-Alcoholic Fatty Liver Disease Study in New York

This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the degree of fat in the liver as measured by magnetic resonance imaging.

Sponsor: Weill Medical College of Cornell University

Who Can Participate

Inclusion Criteria

Age ≥ 18 and \< 65 years old
Must provide signed written informed consent and agree to comply with the study protocol
BMI \>25 kg/m²
Baseline liver fat content of at least 10% as measured by MRI-PDFF

Exclusion Criteria

Unclear etiology of liver disease
Competing etiologies for hepatic steatosis
Co-existing causes of chronic liver disease according to standard diagnostic testing including, but not restricted to:
Positive hepatitis B surface antigen
Positive hepatitis C virus RNA
Suspicion of drug-induced liver disease
Alcoholic liver disease
Autoimmune hepatitis
Wilson's disease
Hemochromatosis
Primary biliary cholangitis or primary sclerosing cholangitis
Known or suspected hepatocellular carcinoma
Current or recent history (\<5 years) of significant alcohol consumption. For men, significant consumption is defined as \>30g of alcohol per day. For women, it is defined as \>20g of alcohol per day.
Compensated and decompensated cirrhosis (clinical and/or histologic evidence of cirrhosis). NASH patients with fibrosis stage = 4 according to the NASH CRN fibrosis staging system are excluded.
Reduction in weight by ≥ 5% within the prior 90 days
Current fasting for ≥ 12 hours per day on the majority of days each week
Pregnant females
Mental instability or incompetence, such that the validity of the informed consent or ability to be compliant with the study is uncertain
Inability to perform MRI-PDFF and/or study as defined below
Inability to medically perform prolonged fasting (i.e. insulin regimen)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05332613) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Alcoholic Fatty Liver Disease Treatment Options in New York, NY

If you're searching for non-alcoholic fatty liver disease treatment options in New York, NY, this clinical trial (NCT05332613) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-alcoholic fatty liver disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-alcoholic fatty liver disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in New York, NY

See all ankylosing spondylitis clinical trials recruiting in New York — not just this study.

Browse Ankylosing Spondylitis Trials in New York →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsNASH TrialsLiver Disease TrialsInterstitial Cystitis TrialsNon-Alcoholic Fatty Liver Disease TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY